JP2014521353A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521353A5
JP2014521353A5 JP2014524110A JP2014524110A JP2014521353A5 JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5 JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014524110 A JP2014524110 A JP 2014524110A JP 2014521353 A5 JP2014521353 A5 JP 2014521353A5
Authority
JP
Japan
Prior art keywords
vaccinia virus
present
culture
hela cells
roller bottle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014524110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521353A (ja
JP6243333B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/049550 external-priority patent/WO2013022764A1/en
Publication of JP2014521353A publication Critical patent/JP2014521353A/ja
Publication of JP2014521353A5 publication Critical patent/JP2014521353A5/ja
Application granted granted Critical
Publication of JP6243333B2 publication Critical patent/JP6243333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014524110A 2011-08-05 2012-08-03 ワクシニアウィルスの生成のための方法および組成物 Active JP6243333B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515724P 2011-08-05 2011-08-05
US61/515,724 2011-08-05
PCT/US2012/049550 WO2013022764A1 (en) 2011-08-05 2012-08-03 Methods and compositions for production of vaccina virus

Publications (3)

Publication Number Publication Date
JP2014521353A JP2014521353A (ja) 2014-08-28
JP2014521353A5 true JP2014521353A5 (cg-RX-API-DMAC7.html) 2016-10-20
JP6243333B2 JP6243333B2 (ja) 2017-12-06

Family

ID=46650950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524110A Active JP6243333B2 (ja) 2011-08-05 2012-08-03 ワクシニアウィルスの生成のための方法および組成物

Country Status (12)

Country Link
US (3) US9719105B2 (cg-RX-API-DMAC7.html)
EP (1) EP2739293B1 (cg-RX-API-DMAC7.html)
JP (1) JP6243333B2 (cg-RX-API-DMAC7.html)
KR (1) KR102022952B1 (cg-RX-API-DMAC7.html)
CN (1) CN103732236B (cg-RX-API-DMAC7.html)
AU (1) AU2012294606B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014000787B1 (cg-RX-API-DMAC7.html)
CA (1) CA2841831C (cg-RX-API-DMAC7.html)
DK (1) DK2739293T3 (cg-RX-API-DMAC7.html)
ES (1) ES2813413T3 (cg-RX-API-DMAC7.html)
PL (1) PL2739293T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013022764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
EP3256156B1 (en) 2015-02-13 2025-02-12 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2017037523A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization
CN106676071B (zh) * 2015-11-06 2019-07-19 天士力创世杰(天津)生物制药有限公司 HeLa-F细胞及其用途
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
JP7110203B2 (ja) 2016-12-28 2022-08-01 トランジェーヌ 腫瘍溶解性ウイルスおよび治療用分子
US20200085891A1 (en) 2017-04-21 2020-03-19 Sillajen, Inc Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3973973A1 (en) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
AU2019384164A1 (en) * 2018-11-21 2021-06-03 Kalivir Immunotherapeutics, Inc. Manufacture of virus
MX2021007860A (es) 2018-12-28 2021-10-26 Transgene Poxvirux deficiente en m2.
KR102228267B1 (ko) 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
CA3183701A1 (en) 2020-06-22 2021-12-30 Sung Jin Kim Method for large scale-production of vaccinia virus using suspension cells
WO2022013221A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
KR20230110545A (ko) 2020-11-19 2023-07-24 칼리버 임뮤노쎄라퓨틱스, 인크. 종양 미세환경 재형성에 의한 종양용해 면역요법
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114395538A (zh) * 2022-01-19 2022-04-26 和元生物技术(上海)股份有限公司 一种促进重组病毒载体向细胞外分泌的方法
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
JP2025523573A (ja) 2022-07-01 2025-07-23 トランジェーヌ サーファクタントタンパク質-dとtnfsfのメンバーを含んでなる融合タンパク質
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
WO2024188802A1 (en) * 2023-03-10 2024-09-19 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
PT1335987E (pt) * 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
KR20120002613A (ko) 2002-08-12 2012-01-06 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
JP5326155B2 (ja) * 2006-08-07 2013-10-30 一般財団法人化学及血清療法研究所 痘瘡生ワクチンの製造方法
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
EP2459701A1 (en) 2009-07-28 2012-06-06 Corning Inc. Synthetic microcarriers for culturing cells
ES2671570T3 (es) * 2009-09-14 2018-06-07 Sillajen Biotherapeutics, Inc. Terapia combinada contra el cáncer con virus oncolítico de vaccinia

Similar Documents

Publication Publication Date Title
JP2014521353A5 (cg-RX-API-DMAC7.html)
US8778675B2 (en) Immortalized avian cell lines and use thereof
JP2019201661A5 (cg-RX-API-DMAC7.html)
JP6243333B2 (ja) ワクシニアウィルスの生成のための方法および組成物
JP2012507270A5 (cg-RX-API-DMAC7.html)
JP2004501647A5 (cg-RX-API-DMAC7.html)
WO2020076820A3 (en) Compositions and methods for preparing viral vectors
JP2009528843A5 (cg-RX-API-DMAC7.html)
CN115785280B (zh) 重组人源纤连蛋白及其在毕赤酵母中的表达方法
JP2013507935A5 (cg-RX-API-DMAC7.html)
CN104087613B (zh) 基于aav‑itr的基因表达微载体及其构建方法和应用
Irie et al. Sendai virus C proteins regulate viral genome and antigenome synthesis to dictate the negative genome polarity
JP2025169249A5 (cg-RX-API-DMAC7.html)
EP4488367A1 (en) Rhabdovirus negative spodoptera frugiperda insect cell strain, screening therefor, identification thereof and use thereof
CN111484972A (zh) 一种从儿童包皮培养获得具备多向分化潜能和免疫调节功能间充质干细胞的方法
Galante et al. Identification and characterization of Orf viruses isolated from sheep and goats in Southern Italy
Bratt et al. Genetics and paragenetic phenomena of paramyxoviruses
CN113583980A (zh) 一种猪繁殖与呼吸综合征突变病毒及其构建方法与应用
Grose et al. Purification and molecular anatomy of the varicella-zoster virion.
CN111662883A (zh) 一种制备及纯化溶瘤病毒的方法及重组溶瘤弹状病毒
Slovic et al. Genetic variability and sequence relatedness of matrix protein in viruses of the families paramyxoviridae and pneumoviridae
CN104774873B (zh) 一种体外组装草鱼呼肠孤病毒制备方法
Saghi et al. Biochemical characterization of temperature-sensitive rabies virus mutants
JPWO2023066874A5 (cg-RX-API-DMAC7.html)
Simms Airway epithelial cell regulation of T cell responses during viral infection